Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. - Test2 - elhamkhani - TriplyDB

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

http://www.wikidata.org/entity/Q36128797

about

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date Sacubitril/valsartan in heart failure: latest evidence and place in therapy Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failur From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.Sacubitril/valsartan (LCZ696) for the treatment of heart failure.Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Neprilysin and Natriuretic Peptide Regulation in Heart Failure.Angiotensin-Neprilysin Inhibition as a Paradigm for All?Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.Current Pharmacological Therapies in Heart Failure Patients.New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study.The need to apply the best therapy in heart failure - the era after PARADIGM-HF.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.The Role of Neprilysin Inhibitors in Cardiovascular Disease.Angiotensin Receptor-Neprilysin Inhibition.Current Therapeutic Options for Heart Failure in Elderly Patients.Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology.Meeting report of the 8th International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017.Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.Drug treatment of heart failure in the elderly.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.[Acute and chronic heart failure].Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.Has the 'epidemic' of heart failure been replaced by a tsunami of co-morbidities?The year in cardiology 2016: heart failure.Sacubitril/Valsartan (LCZ696) in Heart Failure Improving outcomes in heart failure: a personal perspective Entresto therapy effectively protects heart and lung against transverse aortic constriction induced cardiopulmonary syndrome injury in rat

P2860

Q26747165-C241C8B3-C0CF-4198-9F07-B6EB0591A67E Q28070064-9128A69F-F72C-4B3D-A63A-8E9FFBE4A62B Q28070191-94FE6283-F693-4516-AC25-CE0AF67C2054 Q37597972-CE1459A1-34A3-4051-8D31-4A34018C9868 Q38385479-EDFFAF69-924D-4E52-B67D-A103D3BF44B7 Q38612665-EB66E602-5A8F-48D4-844D-707D1A7B59B5 Q38661061-87ACF76E-D5E0-4A60-A13D-BEEE1106243D Q38731859-E00636F2-60BB-4728-A5FF-0EE261C1E2FC Q38754215-BD00E9A4-2E7F-497F-B8E9-74BC5C12C4C3 Q38781645-2979ED1D-79E7-4551-86AC-60DE3B6D9933 Q38788603-6DAD2E92-D489-4E0A-8652-03AA56163C4E Q38790076-DF269D4A-571D-4C50-AA36-304309897602 Q38853482-F5555FFA-B369-444D-A262-C912EEBA9270 Q38982213-CAB4DA3B-CB68-45D3-B469-607E37AC91DC Q39011741-E048909F-3C9D-4743-B453-A05A1C36E504 Q39192295-F101C731-5EC9-4AD4-BCDA-BFDBF7ABDF4C Q39204290-C65843EF-D01D-4E67-AF3E-B68E3798FB69 Q39218629-AB58AE01-D34F-43AB-8055-329D0CB068EF Q39247505-468710E9-2F39-42D7-9604-5E73337CA0D3 Q40000430-3F4115B9-6179-41EA-AEB1-CD6D536114E2 Q40406413-98C2F300-9D16-45DF-B2B8-7D797B6A66AA Q41549509-1AC76E9F-5BEC-4192-8CCA-51E6E8880BBB Q41549636-6925B5CF-83B0-481C-B713-C1083F099E48 Q42373826-8BD72C5C-91E4-42DD-8CF4-66D1516C23E7 Q42700358-2586AE3F-7840-4ECE-B02D-B7E514CAB269 Q46770238-D941C15C-5C2A-4DA5-B3BE-3CCE470BB6D2 Q47121564-6ED82960-C9F2-4BDE-AC5B-FE4296C09F30 Q47642528-12CC5FB0-5784-4E72-B662-5837B0286A75 Q47904506-DEB62B65-3E62-4EFE-90F0-68AA237B3E88 Q49972504-592ED1B7-5D7B-48E8-AA30-F05F1A93CD70 Q50014420-1305E6A1-E77C-46DD-BE28-B60A344353A2 Q50634411-1D277654-319B-4C90-96AB-2E2E3032256B Q50660284-5FC048B9-7343-46C2-AF7C-3B7E8CA23EBE Q52821448-6ADDCFBE-729B-48DF-8B01-EF5116CB3DF8 Q53035483-1ACFF0DE-2385-4592-8BC0-1A8FFF0A3459 Q53784990-E1A7C4BC-BE22-423F-8B39-797C41AE12C4 Q53798859-BD407DF7-EE02-4234-8F70-C8719F114C15 Q57396137-DA641216-B67D-42E0-BD45-9A8099A00166 Q57396162-2A5A0D6B-A9C6-41F2-9584-5E47DBCF6AB1 Q58776088-433F1E1A-51CC-48AB-AC98-EF83E0E9510F

P2860

Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

http://www.wikidata.org/entity/Q36128797

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@ast

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@en

type

label

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@ast

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@en

prefLabel

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@ast

Efficacy and safety of LCZ696 ...... ge: insights from PARADIGM-HF.

@en

P1433

Q36128797-EE29974E-6BA2-44CC-B777-117CD4263F97

P1476

Q36128797-510AD0B6-465C-40B2-83F3-48DF43812CF1

P2093

Q36128797-0AAC5201-216B-4F68-97F4-3ADF2858BE5A

Q36128797-0B7BBDB8-D9FF-4C0A-A79B-9901CC2C568E

Q36128797-1FDE8159-0960-416F-A33B-9F504475216C

Q36128797-25DADD12-A8B6-4D71-AFF7-4145E53D44C3

Q36128797-4DC529A3-8C7F-4CFB-9AEE-69B87289EE06

Q36128797-4E289BCE-A353-45D5-A73D-840AF353CF2D

Q36128797-5BDA5B0B-D0BB-4EB8-9F5E-8F8A5FC602B8

Q36128797-64B491CA-EC8D-4B03-AD48-EF15EA3A27A6

Q36128797-82C9E72C-BD2C-47BA-8860-957EA336CE13

Q36128797-96E6C279-EA59-49B5-B87A-DEC51840C42A

P2860

Q36128797-00929BA7-A82C-4AEB-86F7-62CF68CE628E

Q36128797-01A4C7D3-3A8E-4515-A231-248A060C6D09

Q36128797-0CDD98FB-2760-4DBD-9F21-8090BF8F9188

Q36128797-1C6CC90D-5550-4EB1-91BF-E81E5D7850F2

Q36128797-1E8D89C5-9354-4FFF-A5BE-76D197BFA431

Q36128797-260C7352-C976-4BE3-BDF7-0F1CD0E8DF32

Q36128797-3982C5EC-8BB8-4563-87D2-CFA08B97E65F

Q36128797-44BCF692-CF99-44E7-99D8-13D3D70B8117

Q36128797-54B7E089-26CC-454E-AD0F-A58C4B9D38DD

Q36128797-5F35A1E4-B31C-4DF1-88B5-49E35E331FF5

P304

Q36128797-CC5A5E0C-0C76-4AE8-89A0-6A06A4173224

P31

Q36128797-1BC5DDCC-0557-42FB-B400-21211EF507C3

P356

Q36128797-E7238971-6EB1-4CB5-9674-A47AF0C1A481

P433

Q36128797-7BEEFC9A-1398-4013-A9A0-36075209F96C

P478

Q36128797-89ADA996-8A2B-46FB-9B5E-E80504B241CB

P50

Q36128797-046775DF-4DEA-41E4-A39F-38AA4C0E25B1

Q36128797-14DB8CD5-A85A-4B21-9A93-62389F7B0CFD

Q36128797-2B6FF8DD-82AE-42D4-AF8E-D54632041CB7

P577

Q36128797-68B65665-2117-4EC5-9CB7-EA61D751DA64

P5875

Q36128797-B30B1ED6-E1A3-40EC-A9C2-1DA5AAADCF73

P698

Q36128797-B506C1F0-12C5-4249-9492-9DAD3FC3605D

P932

Q36128797-D4AC5756-3FC8-4D29-AE60-8E9B165D5A7C

P356

P1433

European Heart Journal

P1476

Efficacy and safety of LCZ696 ...... age: insights from PARADIGM-HF

@en

P2093

Adel R Rizkala

http://www.w3.org/2001/XMLSchema#string

Akshay S Desai

http://www.w3.org/2001/XMLSchema#string

Arvo Rosenthal

http://www.w3.org/2001/XMLSchema#string

Chen-Huan Chen

http://www.w3.org/2001/XMLSchema#string

Edmundo Bayram

http://www.w3.org/2001/XMLSchema#string

Jean L Rouleau

http://www.w3.org/2001/XMLSchema#string

Karl Swedberg

http://www.w3.org/2001/XMLSchema#string

Marta Negrusz-Kawecka

http://www.w3.org/2001/XMLSchema#string

Martin P Lefkowitz

http://www.w3.org/2001/XMLSchema#string

Michael Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.

Heart failure care in low- and middle-income countries: a systematic review and meta-analysis.

Heart failure in elderly patients: distinctive features and unresolved issues.

Increased comorbidities in heart failure patients ≥ 85 years but declined from >90 years: data from the Swedish Heart Failure Registry.

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Heart failure in older adults.

Treatment of systolic heart failure in the elderly: an evidence-based review.

Pharmacotherapy of heart failure in the elderly: adverse events.

Systolic heart failure in the elderly: optimizing medical management.

P304

2576-2584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV330

http://www.w3.org/2001/XMLSchema#string

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Pardeep S. Jhund

P577

2015-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280602597

http://www.w3.org/2001/XMLSchema#string

P698

26231885

http://www.w3.org/2001/XMLSchema#string

P932

4595742

http://www.w3.org/2001/XMLSchema#string